Pulse Biosciences, Inc. (PLSE)

NASDAQ: PLSE · IEX Real-Time Price · USD
8.69
+0.29 (3.39%)
Mar 28, 2024, 3:00 PM EDT - Market open

Company Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.

It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.

The company was incorporated in 2014 and is headquartered in Hayward, California.

Pulse Biosciences, Inc.
Pulse Biosciences logo
Country United States
Founded 2014
IPO Date May 18, 2016
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 61
CEO Kevin P. Danahy

Contact Details

Address:
3957 Point Eden Way
Hayward, California 94545
United States
Phone 510-906-4600
Website pulsebiosciences.com

Stock Details

Ticker Symbol PLSE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001625101
CUSIP Number 74587B101
ISIN Number US74587B1017
Employer ID 46-5696597
SIC Code 3841

Key Executives

Name Position
Robert W. Duggan Executive Chairman
Kevin P. Danahy President and Chief Executive Officer
Darrin R. Uecker Chief Technology Officer and Director
Mitchell E. Levinson Chief Strategy Officer
Dr. Richard Nuccitelli Ph.D. Chief Science Officer
Kenneth B. Stratton Esq., J.D. General Counsel and Corporate Secretary
Patty Perla Vice President of Human Resources
David Danitz Senior Vice President of Engineering
Dr. Gansevoort Dunnington M.D. Chief Medical Officer
Dr. Niv Ad M.D. Chief Science Officer of Cardiac Surgery

Latest SEC Filings

Date Type Title
Mar 11, 2024 8-K Current Report
Feb 14, 2024 8-K Current Report
Jan 9, 2024 8-K Current Report
Jan 2, 2024 8-K Current Report
Dec 22, 2023 8-K Current Report
Dec 20, 2023 8-K Current Report
Dec 15, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Dec 4, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 27, 2023 DEF 14A Other definitive proxy statements
Nov 27, 2023 8-K Current Report